|
BANGKOK, Feb. 6, 2026 /PRNewswire/ -- IHG Hotels & Resorts announces the opening of voco Bangkok Surawong, marking the debut of IHG's fastest growing premium brand, voco hotels, in Thailand.
Each voco property is characterised by its individual charm, which provides guests with something unique while creating an inviting and unstuffy atmosphere for guests to truly unwind and feel at ease. Infused with charming personal touches and subtle Thai influences, voco Bangkok Surawong is a great gateway to explore Bangkok.
"We are thrilled to introduce voco hotels to Thailand, and offer travellers a stay that is upscale, familiar yet refreshingly different. We look forward to inviting guests to immerse in the brand's playful nature and enjoy delightful, uplifting voco experiences provided by our thoughtful hosts here in Surawong," said Walid Ouezini, General Manager, voco Bangkok Surawong.
Award-winning Thai architecture firm A49 refashioned the Brutalist modernism of the original Tawana Hotel, by blending heritage with contemporary openness through preserved geometric forms, natural light, and thoughtful architectural flow. Within the hotel, Thai interior design studio, P49 Deesign brings mid-century charm to life in true voco's warm, playful style—balancing retro character, Thai artistry and modern comfort to reflect Surawong's vibrant spirit.
Guests are invited to 'come on in' and are greeted with a signature voco welcome treat that is unique and representative of the local area, and a swift check-in. At voco Bangkok Surawong, guests will enjoy mango sticky rice cookie – a modern take on the classic Thai dessert that is carefully prepared by the hotel's pastry chef daily with fresh local mangoes.
'Me time' beckons in its 244 thoughtfully designed guestrooms and suites. Staying true to voco hotel's "step by step" sustainability mantra, voco Bangkok Surawong is committed to innovation and sustainability, and the belief that small steps collectively make the biggest difference. This includes pillows and duvet fillings made from recycled materials and premium organic New Zealand bulk bath amenities from Antipodes.
Outstanding dining experiences offer a taste of the 'voco life' at the hotel's three dynamic restaurants and bars, including:
- Tasca Sabio – a spirited Spanish-inspired restaurant and bar where bold Mediterranean flavours, lively sangria rituals and small plates made for sharing create an atmosphere perfect for friends to gather.
- Deckles Smokehouse – the all-day-dining restaurant that offers a Bangkok's premium hotel smokehouse experience, where slow-smoking traditions meet vibrant spices and craft cocktails
Additional amenities include a full lap pool set amidst landscaped gardens on the fourth floor, 24-hour fitness centre and an onsen spa.
The hotel also offers an elegant ballroom that seats up to 200 guests as well as four flexible meeting room spaces with the latest AV tech and stylish contemporary interiors – suitable for mid-scale conferences, events, and meetings.
Located along Surawong Road, the hotel sits at the midst of Bangkok's heritage and modern energy—steps away from the bustling Silom district, Sathorn's corporate hub, and Siam's shopping and entertainment landmarks. With its lively neighbourhood charm, Surawong has long been known as a place of welcome, making it the perfect home for voco's warm, stylish, and refreshingly different approach to hospitality.
Launched in 2018, voco hotels by IHG has quickly become one of IHG Hotels & Resorts' fastest growing with 117 open hotels and 108 exciting destinations in the pipeline, including the recently opened voco Quang Binh Resort and voco Bandung Setiabudi.
For more information on voco Bangkok Surawong, please visit http://www.vocohotels.com/bkksurawong.
Press Kit available here and please credit IHG Hotels & Resorts for use of images.
| *Figures as of 30 September 2025 |
BANGKOK, Feb. 6, 2026 /PRNewswire/ -- IHG Hotels & Resorts announces the opening of voco Bangkok Surawong, marking the debut of IHG's fastest growing premium brand, voco hotels, in Thailand.
Each voco property is characterised by its individual charm, which provides guests with something unique while creating an inviting and unstuffy atmosphere for guests to truly unwind and feel at ease. Infused with charming personal touches and subtle Thai influences, voco Bangkok Surawong is a great gateway to explore Bangkok.
"We are thrilled to introduce voco hotels to Thailand, and offer travellers a stay that is upscale, familiar yet refreshingly different. We look forward to inviting guests to immerse in the brand's playful nature and enjoy delightful, uplifting voco experiences provided by our thoughtful hosts here in Surawong," said Walid Ouezini, General Manager, voco Bangkok Surawong.
Award-winning Thai architecture firm A49 refashioned the Brutalist modernism of the original Tawana Hotel, by blending heritage with contemporary openness through preserved geometric forms, natural light, and thoughtful architectural flow. Within the hotel, Thai interior design studio, P49 Deesign brings mid-century charm to life in true voco's warm, playful style—balancing retro character, Thai artistry and modern comfort to reflect Surawong's vibrant spirit.
Guests are invited to 'come on in' and are greeted with a signature voco welcome treat that is unique and representative of the local area, and a swift check-in. At voco Bangkok Surawong, guests will enjoy mango sticky rice cookie – a modern take on the classic Thai dessert that is carefully prepared by the hotel's pastry chef daily with fresh local mangoes.
'Me time' beckons in its 244 thoughtfully designed guestrooms and suites. Staying true to voco hotel's "step by step" sustainability mantra, voco Bangkok Surawong is committed to innovation and sustainability, and the belief that small steps collectively make the biggest difference. This includes pillows and duvet fillings made from recycled materials and premium organic New Zealand bulk bath amenities from Antipodes.
Outstanding dining experiences offer a taste of the 'voco life' at the hotel's three dynamic restaurants and bars, including:
- Tasca Sabio – a spirited Spanish-inspired restaurant and bar where bold Mediterranean flavours, lively sangria rituals and small plates made for sharing create an atmosphere perfect for friends to gather.
- Deckles Smokehouse – the all-day-dining restaurant that offers a Bangkok's premium hotel smokehouse experience, where slow-smoking traditions meet vibrant spices and craft cocktails
Additional amenities include a full lap pool set amidst landscaped gardens on the fourth floor, 24-hour fitness centre and an onsen spa.
The hotel also offers an elegant ballroom that seats up to 200 guests as well as four flexible meeting room spaces with the latest AV tech and stylish contemporary interiors – suitable for mid-scale conferences, events, and meetings.
Located along Surawong Road, the hotel sits at the midst of Bangkok's heritage and modern energy—steps away from the bustling Silom district, Sathorn's corporate hub, and Siam's shopping and entertainment landmarks. With its lively neighbourhood charm, Surawong has long been known as a place of welcome, making it the perfect home for voco's warm, stylish, and refreshingly different approach to hospitality.
Launched in 2018, voco hotels by IHG has quickly become one of IHG Hotels & Resorts' fastest growing with 117 open hotels and 108 exciting destinations in the pipeline, including the recently opened voco Quang Binh Resort and voco Bandung Setiabudi.
For more information on voco Bangkok Surawong, please visit http://www.vocohotels.com/bkksurawong.
Press Kit available here and please credit IHG Hotels & Resorts for use of images.
*Figures as of 30 September 2025
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
voco Bangkok Surawong: The first property under voco hotels opens in Thailand
|
Demonstrating Instantaneous Ablation Through High-Voltage Waveforms and Efficient Point-by-Point Pulsed Field Ablation
CARDIFF-BY-THE-SEA, Calif., Feb. 6, 2026 /PRNewswire/ -- Field Medical, Inc., a clinical-stage medical technology company advancing pulsed field ablation (PFA) solutions for complex cardiac arrhythmias, today announced the presentation of late breaking clinical trial data from the first-in-human Field PULSE study at the 31st Annual International AF Symposium 2026, held February 5–7 in Boston.
Field PULSE evaluates a novel high-voltage, sub-second pulsed field waveform delivered through Field Medical's FieldForce™ Ablation System and Catheter, a focal, contact-sensing catheter, enabling instantaneous ablation through point-by-point energy delivery without reliance on prolonged tissue-catheter contact. The study was selected for a Late Breaking Clinical Trial (LBCT) presentation.
"By eliminating the need for sustained tissue-catheter contact, sub-second pulsed field delivery enables both efficient point-by-point ablation and individualized lesion sets," said Vivek Y. Reddy, M.D., principal investigator of Field PULSE and electrophysiologist at Mount Sinai, New York. "This approach preserves the flexibility physicians expect from focal ablation while delivering the procedural efficiency associated with pulsed field technologies."
Study Highlights
- Instantaneous energy delivery: Lesions created in less than 200 milliseconds, enabling rapid point-by-point ablation
- Procedural efficiency: Median bilateral pulmonary vein isolation (PVI) time of 12.5 minutes, with the fastest case completed in 7.7 minutes
- PVI durability: Remapping demonstrated progressive improvement in PVI durability with the optimized waveform
- By vein: 94.2%
- By patient: 84.6%
- Safety outcomes:
- No device-related serious adverse events
- No acute kidney injury, reported phrenic nerve palsy or clinically relevant hemolysis
- Among patients evaluated by brain MRI (n=14), no silent cerebral lesions (DWI+/FLAIR+) were observed
These findings extend Field Medical's body of clinical evidence of its high-voltage focal PFA approach beyond ventricular arrhythmias and into the development of therapy for atrial fibrillation (AF). Together with previously reported six-month first-in-human ventricular tachycardia (VT) data, the results support the emergence of a versatile ablation platform for all chambers of the heart, designed to enable focal PFA across atrial and ventricular substrates while preserving procedural efficiency.
"The Field PULSE results reinforce our approach of deliberately architecting focal PFA to address the fundamental limitations of existing methods, then validating its application through data," said Steven Mickelsen, M.D., founder and chief technology officer of Field Medical. "By delivering each ablation point in a fraction of a second, we reduce dependence on prolonged catheter stability, limit the impact of cardiac motion and establish a platform approach for treating complex arrhythmias."
The Field PULSE data were presented during the Late Breaking Clinical Trials Session I at AF Symposium 2026. Field Medical will be featured on Friday, February 6, from 7:30–8:30 a.m. during a scientific session on the biophysics of PFA for AF, including a presentation titled Maximizing Lesion Depth Using High Voltage PFA Waveform by Kenneth Ellenbogen, M.D., and during Case Transmission Session 6 on Saturday, February 7, from 7:30–9:30 a.m., highlighting AF Ablation Using a High-Voltage Field Medical PFA Catheter, presented by Vivek Reddy, M.D., using the FieldForce Ablation System and FieldForce Ablation Catheter.
About FieldForce™ Ablation System
The FieldForce Ablation System is a focal, contact-sensing PFA system built on proprietary FieldBending™ technology to deliver targeted, high-intensity electric fields using a novel pulsed energy delivery strategy. Designed to support both atrial and ventricular ablation, the system serves as a universal ablation platform for the heart and beyond. The FieldForce system is designed to enable targeted and tailored ablation treatment while platform features focus on procedural efficiency.
About Field Medical®, Inc.
Founded in 2022 by Steven Mickelsen, M.D., Field Medical is a clinical-stage medical technology company committed to advancing pulsed field ablation (PFA) solutions for complex cardiac arrhythmias. Its FieldForce Ablation System integrates a focal catheter design with proprietary FieldBending energy designed to safely deliver efficient, precise ablation with the goal of improving outcomes in ventricular and atrial arrhythmia treatment. In 2024, Field Medical earned Breakthrough Device Designation and gained entry into the FDA TAP Pilot Program for its ventricular tachycardia indication. In October 2025, the VCAS trial was published in Circulation.
For more information, visit www.fieldmedicalinc.com and follow us on LinkedIn, X, and YouTube.
The FieldForce™ Ablation System is an investigational device and is limited by federal (or United States) law to investigational use.
Media Contact
Holly Windler
619.929.1275
holly.windler@gmail.com
media@fieldmedicalinc.com
Photo - https://mma.prnasia.com/media2/2878123/Field_Medical_Ablation_System.jpg?p=medium600
Logo - https://mma.prnasia.com/media2/2574173/Field_Medical_Logo_Block_WhiteOnBlack_Logo.jpg?p=medium600
Demonstrating Instantaneous Ablation Through High-Voltage Waveforms and Efficient Point-by-Point Pulsed Field Ablation
CARDIFF-BY-THE-SEA, Calif., Feb. 6, 2026 /PRNewswire/ -- Field Medical, Inc., a clinical-stage medical technology company advancing pulsed field ablation (PFA) solutions for complex cardiac arrhythmias, today announced the presentation of late breaking clinical trial data from the first-in-human Field PULSE study at the 31st Annual International AF Symposium 2026, held February 5–7 in Boston.
Field PULSE evaluates a novel high-voltage, sub-second pulsed field waveform delivered through Field Medical's FieldForce™ Ablation System and Catheter, a focal, contact-sensing catheter, enabling instantaneous ablation through point-by-point energy delivery without reliance on prolonged tissue-catheter contact. The study was selected for a Late Breaking Clinical Trial (LBCT) presentation.
"By eliminating the need for sustained tissue-catheter contact, sub-second pulsed field delivery enables both efficient point-by-point ablation and individualized lesion sets," said Vivek Y. Reddy, M.D., principal investigator of Field PULSE and electrophysiologist at Mount Sinai, New York. "This approach preserves the flexibility physicians expect from focal ablation while delivering the procedural efficiency associated with pulsed field technologies."
Study Highlights
- Instantaneous energy delivery: Lesions created in less than 200 milliseconds, enabling rapid point-by-point ablation
- Procedural efficiency: Median bilateral pulmonary vein isolation (PVI) time of 12.5 minutes, with the fastest case completed in 7.7 minutes
- PVI durability: Remapping demonstrated progressive improvement in PVI durability with the optimized waveform
- By vein: 94.2%
- By patient: 84.6%
- No device-related serious adverse events
- No acute kidney injury, reported phrenic nerve palsy or clinically relevant hemolysis
- Among patients evaluated by brain MRI (n=14), no silent cerebral lesions (DWI+/FLAIR+) were observed
These findings extend Field Medical's body of clinical evidence of its high-voltage focal PFA approach beyond ventricular arrhythmias and into the development of therapy for atrial fibrillation (AF). Together with previously reported six-month first-in-human ventricular tachycardia (VT) data, the results support the emergence of a versatile ablation platform for all chambers of the heart, designed to enable focal PFA across atrial and ventricular substrates while preserving procedural efficiency.
"The Field PULSE results reinforce our approach of deliberately architecting focal PFA to address the fundamental limitations of existing methods, then validating its application through data," said Steven Mickelsen, M.D., founder and chief technology officer of Field Medical. "By delivering each ablation point in a fraction of a second, we reduce dependence on prolonged catheter stability, limit the impact of cardiac motion and establish a platform approach for treating complex arrhythmias."
The Field PULSE data were presented during the Late Breaking Clinical Trials Session I at AF Symposium 2026. Field Medical will be featured on Friday, February 6, from 7:30–8:30 a.m. during a scientific session on the biophysics of PFA for AF, including a presentation titled Maximizing Lesion Depth Using High Voltage PFA Waveform by Kenneth Ellenbogen, M.D., and during Case Transmission Session 6 on Saturday, February 7, from 7:30–9:30 a.m., highlighting AF Ablation Using a High-Voltage Field Medical PFA Catheter, presented by Vivek Reddy, M.D., using the FieldForce Ablation System and FieldForce Ablation Catheter.
About FieldForce™ Ablation System
The FieldForce Ablation System is a focal, contact-sensing PFA system built on proprietary FieldBending™ technology to deliver targeted, high-intensity electric fields using a novel pulsed energy delivery strategy. Designed to support both atrial and ventricular ablation, the system serves as a universal ablation platform for the heart and beyond. The FieldForce system is designed to enable targeted and tailored ablation treatment while platform features focus on procedural efficiency.
About Field Medical®, Inc.
Founded in 2022 by Steven Mickelsen, M.D., Field Medical is a clinical-stage medical technology company committed to advancing pulsed field ablation (PFA) solutions for complex cardiac arrhythmias. Its FieldForce Ablation System integrates a focal catheter design with proprietary FieldBending energy designed to safely deliver efficient, precise ablation with the goal of improving outcomes in ventricular and atrial arrhythmia treatment. In 2024, Field Medical earned Breakthrough Device Designation and gained entry into the FDA TAP Pilot Program for its ventricular tachycardia indication. In October 2025, the VCAS trial was published in Circulation.
For more information, visit www.fieldmedicalinc.com and follow us on LinkedIn, X, and YouTube.
The FieldForce™ Ablation System is an investigational device and is limited by federal (or United States) law to investigational use.
Media Contact
Holly Windler
619.929.1275
holly.windler@gmail.com
media@fieldmedicalinc.com
Photo - https://mma.prnasia.com/media2/2878123/Field_Medical_Ablation_System.jpg?p=medium600
Logo - https://mma.prnasia.com/media2/2574173/Field_Medical_Logo_Block_WhiteOnBlack_Logo.jpg?p=medium600
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Field Medical Presents Late Breaking Field PULSE Trial Data at AF Symposium 2026
